The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082 as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes.
The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082 as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes.
The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082 as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes.
The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082 as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes.
Increased use of single-use systems has led to a need to redefine safe, stable and integral systems for shipping biopharmaceuticals around the world. This article provides qualification data under international ASTM D4169 norms.
An effective supplier-initiated change management process is discussed.
The Australian pharmaceutical market offers opportunities for manufacturers despite challenges.
The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products.
The author provides a review of the concepts of design and qualification that apply to single-use systems.
Integrating advances in facility design can meet differing and emerging bioprocessing needs.
Changes in the country’s political landscape may affect the pharmaceutical industry market in the future.
A study to investigate metacomplex formation in the hetero-association of a multivalent antigen, streptavidin (SA), and a bivalent antibody (Ab) using a composition-gradient multiangle light-scattering (CG-MALS) system consisting of a composition-gradient device, a MALS detector, and a UV/Vis absorption detector.
A study to investigate metacomplex formation in the hetero-association of a multivalent antigen, streptavidin (SA), and a bivalent antibody (Ab) using a composition-gradient multiangle light-scattering (CG-MALS) system consisting of a composition-gradient device, a MALS detector, and a UV/Vis absorption detector.
Along with particulate control and determination, speakers at the June conference in Rockville, Maryland, examined the role of protein aggregation and immunogenicity
The author describes a method to avoid protein aggregation when using light scattering systems.
Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.
Along with particulate control and determination, speakers at the June conference in Rockville, Maryland, examined the role of protein aggregation and immunogenicity
Patrick Jackson of Vindon Scientific offers key considerations for choosing an outsourced sample storage facility.
FDA talks about the changing scope of regulatory science.
Ontario-area scientists discuss approaches to development of stem-cell therapies.
An international consortium of pharmaceutical companies, academia, research organisations and other related entities have launched a new platform to help enhance drug discovery in Europe.
This month, we rewind to an article titled "Good Manufacturing Practices Training."
US Pharmacopeia develops and improves its class approach for ensuring quality biopharmaceuticals.
At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.
Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.
Patent databases are often overlooked as a source of basic science, research, and development
The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.
As constant scale up grows out of favor in the biopharmaceutical industry, new-and old-approaches are required. The author reviews the state of downstream processing and considers potential solutions, including the streamlining of full processes and borrowed technologies